MARKET

ACHFF

ACHFF

Arch Biopartners
OTCMQB
0.314
NaN%
Opening 09:30 05/22 EDT
OPEN
--
PREV CLOSE
0.314
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
1.410
52 WEEK LOW
0.290
MARKET CAP
21.33M
P/E (TTM)
-10.5369
1D
5D
1M
3M
1Y
5Y
1D
Arch Biopartners says Royal Columbian Hospital doses first patient in Phase II AKI trial
PUBT · 8h ago
ARCH BIOPARTNERS ANNOUNCES ROYAL COLUMBIAN HOSPITAL HAS DOSED ITS FIRST PATIENT IN ITS PHASE II CARDIAC SURGERY-ASSOCIATED AKI TRIAL
Reuters · 8h ago
Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
Barchart · 13h ago
Arch Biopartners grants new director 150,000 stock options at $1.05 per share
PUBT · 04/30 12:30
Arch Biopartners says Royal Columbian Hospital begins recruiting for LSALT Phase II trial
PUBT · 04/30 11:09
Arch Biopartners closes CAD 0.6 million private placement of common shares
Reuters · 04/02 09:45
ARCH BIOPARTNERS CLOSES NON-BROKERED PRIVATE PLACEMENT
Reuters · 04/02 09:45
Arch Biopartners announces CAD 0.6 million private placement of common shares
Reuters · 03/30 10:04
More
About ACHFF
Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute and chronic kidney diseases. The Company is advancing an integrated pipeline that includes new treatments targeting inflammation and toxin-induced kidney injury. Its programs include a pre-clinical chronic kidney disease platform targeting interleukin-32 (IL-32), LSALT peptide, a dipeptidase-1 (DPEP1) inhibitor in Phase II for preventing cardiac surgery-associated acute kidney injury, and cilastatin, a repurposed drug in Phase II for preventing toxin-induced kidney damage. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting millions of patients worldwide. Its LSALT Peptide and cilastatin, are being developed to target kidney injury caused by inflammation or toxins respectively, which are both significant unmet medical needs.

Webull offers Arch Biopartners Inc stock information, including OTCMQB: ACHFF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACHFF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACHFF stock methods without spending real money on the virtual paper trading platform.